News

About Lovastatin

  • Author:Hubei Ocean Biotech Co.,LTd
  • Source:www.oceanchinachem.com
  • Release on :2016-04-20

Pharmacology and Toxicology

Lovastatin competitively inhibit cholesterol synthesis in the body, the speed limit in the process of enzyme hydroxyl methyl glutaric acyl coenzyme A reductase, reduce cholesterol synthesis, also increase the low density lipoprotein receptor synthesis, the main working part in the liver, the result of blood cholesterol and LDL cholesterol levels, thus to atherosclerosis and coronary heart disease prevention and control work. This product also reduce blood serum triglyceride level and increase high density lipoprotein level. In mice, for 3-4 times people dose can cause cancer, but not in large-scale long-term clinical trials in humans, increased tumorigenesis. Mutation of the existing research did not find this product to have.

Pharmacokinetics

Learn this oral absorption is good, but 30% less absorbed on an empty stomach. This product is widely first pass metabolism in the liver, hydrolysis for a variety of metabolites, including mainly beta hydroxy acid three active metabolites. This product and beta hydroxy acid metabolites of protein binding rate is as high as 95%, at the peak time for 2-4 hours, T1/2 to 3 hours. From the eduction of excrement and urine, 83% and 10% from the urine. After long-term treatment discontinuation, role for 4 to 6 weeks.

 Our company Hubei Ocean Biotech Co.,Ltd. mainly supply:APIs,phamraceutical intermediate,inorganic chemicals,organic chemicals,water treatment,food additives and feed additives.Most of them have passed strict quality control system,such as USP,BP,EP,JP,CP,and some of them are under GMP manufacturing.